Piyush Goyal meets EY Global Chair Janet Truncale, eyes GCC investment push
Synopsis
Commerce Minister Piyush Goyal's back-to-back meetings — with EY's global CEO on GCCs and with global ambassadors on pharma — reveal a sharper, sector-specific investment diplomacy. With pharma exports doubling to $31 billion in a decade and GCC momentum building, India is no longer just pitching potential; it is pitching a track record.
Key Takeaways
Commerce Minister Piyush Goyal met EY Global Chair Janet Truncale on 9 June in New Delhi to discuss GCC opportunities and investment avenues.
Truncale also held a separate meeting with Finance Minister Nirmala Sitharaman during the same visit.
India's pharmaceutical exports grew from approximately $14 billion in FY 2014-15 to approximately $31 billion in FY 2025-26 , reaching patients in over 200 countries .
Goyal highlighted India's COVID-19 response as proof of its capacity to supply medicines and vaccines reliably to the Global South .
The meetings reflect a coordinated Centre -level push to attract high-value foreign investment in GCCs and pharmaceuticals.
Commerce and Industry Minister Piyush Goyal on Tuesday, 9 June held a high-level meeting with Janet Truncale, Global Chair and Chief Executive Officer of EY, in New Delhi, focusing on India's expanding role in global supply chains and the growing opportunity around Global Capability Centres (GCCs).
What Was Discussed
'Also discussed investment avenues, given India's strong economic growth momentum and emergence as a preferred global investment destination,' Goyal said in a post on X. The two leaders exchanged views on how India can deepen its integration into global value chains, with GCCs emerging as a key vehicle for attracting high-quality foreign investment and skilled employment.
Notably, Truncale also met Finance Minister Nirmala Sitharaman during her visit to the national capital, signalling a broader government-level engagement with EY's global leadership on economic and investment priorities.
India's Pharma Pitch: A Parallel Push
Separately, Goyal addressed the Global Ambassador Meet on the Pharmaceutical Sector in New Delhi, where he underscored India's credentials as a trusted global healthcare partner. He stated that trust, innovation, and partnership form the foundation of India's pharmaceutical strength, and invited global companies to invest, manufacture, and collaborate in India.
The minister highlighted that India's pharmaceutical exports have grown from approximately $14 billion in FY 2014-15 to approximately $31 billion in FY 2025-26, with Indian medicines now reaching patients in more than 200 countries. He noted that while India retains its leadership in generic medicines, the sector is increasingly pivoting towards innovation-driven, higher-value products.
COVID-19 Legacy and Global South Ties
Goyal recalled India's role during the COVID-19 pandemic, when the country not only met domestic medical requirements but also supplied medicines and vaccines to numerous nations, particularly in the Global South and other emerging economies. He described this as evidence of India's ability to combine quality, reliability, and affordability at scale.
He also drew attention to the sector's growing focus on research, advanced technologies, and contract manufacturing, positioning India as both an innovator and a dependable supplier to the world.
What This Signals
The back-to-back engagements — with EY's global leadership on GCCs and with global ambassadors on pharmaceuticals — reflect a coordinated effort by the Centre to consolidate India's image as a preferred destination for high-value foreign investment. This comes amid intensifying global competition from Vietnam, Mexico, and Eastern Europe for supply chain diversification mandates.
With GCC additions accelerating and pharma exports doubling over a decade, India's investment diplomacy appears to be shifting from broad-based pitches to sector-specific, data-backed outreach. The outcomes of these engagements are expected to feed into upcoming trade and investment framework discussions.
Point of View
High-margin sectors like GCCs and pharma. The doubling of pharmaceutical exports to $31 billion is a credible data point, but the GCC narrative still rests heavily on cost arbitrage rather than capability depth. The real question is whether India can convert these ministerial-level conversations into binding commitments before competing destinations — Vietnam, Poland, Mexico — sharpen their own GCC and manufacturing propositions. The simultaneous engagement with the Finance Minister suggests EY is being courted at the highest levels, which raises the stakes for follow-through.
NationPress
5 Aug 2026
Frequently Asked Questions
What did Piyush Goyal and EY Global Chair Janet Truncale discuss?
They discussed India's growing role in global supply chains, opportunities in Global Capability Centres (GCCs), and investment avenues linked to India's strong economic growth momentum. Goyal shared details of the meeting in a post on X.
Who else did Janet Truncale meet during her India visit?
Janet Truncale also met Finance Minister Nirmala Sitharaman in New Delhi during the same visit, indicating broad government-level engagement with EY's global leadership.
How much have India's pharmaceutical exports grown in the last decade?
India's pharmaceutical exports have grown from approximately $14 billion in FY 2014-15 to approximately $31 billion in FY 2025-26, with medicines now reaching patients in more than 200 countries.
What is India's pitch to global pharmaceutical companies?
Commerce Minister Goyal invited global companies to invest, manufacture, and collaborate in India, positioning the country as an innovator, reliable supplier of affordable medicines, and destination for contract manufacturing and advanced healthcare technologies.
Why are GCCs significant in the context of India's investment push?
Global Capability Centres are high-value offshore units set up by multinational firms for technology, analytics, and business operations. India already hosts a large share of global GCCs, and the government sees further GCC expansion as a key driver of quality foreign investment and skilled employment.
